Alexandria's
highly strategic venture capital platform is an integral component
of the company's unwavering efforts to catalyze innovation in
medicine, a national imperative, across its life science ecosystems
and since 1996 has enabled its early identification of novel
technology platforms and disruptive products that have led to
groundbreaking medicines to meet massive unmet medical need
PASADENA, Calif., Jan. 9, 2023
/PRNewswire/ -- Alexandria Venture Investments, the strategic
venture capital platform of Alexandria Real Estate Equities, Inc.
(NYSE: ARE), the first, preeminent, longest-tenured and pioneering
owner, operator and developer of collaborative life science, agtech
and technology campuses in AAA innovation cluster locations with
over 1,000 tenants, today announced that it was recognized by
Silicon Valley Bank in its "Healthcare Investments and Exits:
Annual Report 2022" as the #1 most active corporate investor in
biopharma by new deal volume (2021–2022) for the sixth consecutive
year. This important distinction demonstrates Alexandria's position as a key leader and
trusted partner within the life science industry. Since the
platform's launch in 1996, Alexandria Venture Investments has
actively invested in world-leading life science companies as well
as promising agrifoodtech and climate innovation companies that are
advancing new, transformative therapeutic modalities and innovative
life science platforms to meaningfully improve human health.
Alexandria's strategic venture
activity, a bedrock of its mission-driven business, continues to
provide deep insights into key macro life science industry and
innovation trends; build and nurture strong relationships with
serial entrepreneurs, world-renowned academic institutions and
venture investors; and further enhance the REIT industry-leading
tenant roster it has diligently cultivated over the years.
"While the life science industry has made incredible strides,
the opportunity to improve human health and disease through the
painstaking research and discovery process of new, novel medicines
remains immense, with over 10,000 known diseases, nearly 90% of
which have no approved treatments or cures. In the face of this
staggering unmet medical need, advancing new and improved therapies
and cures is a national imperative," said Joel S. Marcus, executive chairman and founder
of Alexandria Real Estate Equities, Inc. and founder and head of
Alexandria Venture Investments. "Everyone will encounter health
challenges during their lifetime and shoulder the cost and
provision of care for loved ones as they navigate dementia, mental
illness, cancer, or cardiovascular, metabolic, autoimmune and other
harrowing diseases and disorders. Even for diseases with available
treatments, the unmet need is significant. Individuals with
type 1 diabetes, for example, make an estimated 180 health-related
decisions daily — that's one decision every five minutes. We are
incredibly proud of our more than 25-year history of investing
in highly disruptive companies pioneering cutting-edge therapeutic
platforms that respond to the urgent needs of patients around the
world, including our remarkable early investments in Alnylam and
Moderna. And we are as dedicated as ever to partnering with
trailblazing life science companies to support the development of
life-improving and life-changing treatments and cures."
Alexandria Venture Investments' early investments in Alnylam and
Moderna are tremendous examples of how the company's deep
understanding of the life science industry has enabled its early
identification of and investment in revolutionary technologies that
have led to novel medicines that positively impact the lives of
patients around the world. Recognizing the immense potential of
Alnylam's RNAi technology platform, Alexandria invested in its Series A financing
in 2002. Today, longtime Alexandria tenant Alnylam is the leading RNAi
therapeutics company, having successfully translated Nobel
Prize-winning science into multiple commercial therapeutic products
benefiting patients around the world. In 2012, shortly after
Moderna was founded, Alexandria identified the transformative
potential of the company's pioneering mRNA platform. Alexandria has both invested in and provided
Moderna with mission-critical real estate over the past decade. Now
a world-leader in mRNA therapeutics and vaccines, Moderna has over
20 non-COVID-related products in clinical development in addition
to its COVID-19 vaccines.
Innovative medicines are essential for preventing, treating and
curing disease and a key solution for driving down overall
healthcare costs. The life science industry's pursuit of new,
precise and more effective medicines, including complex modalities
such as cell, gene and RNA-based therapies, represents a
significant growth opportunity for the industry. Alexandria's proactive and disciplined venture
investment activity remains vital to catalyzing the next generation
of groundbreaking therapeutic platforms with immense potential to
address a wide array of diseases, and ultimately fulfilling its
mission to advance human health by curing disease and improving
nutrition. The most impactful innovation of the 21st century is at
the intersection of biology and technology, for which the future
prospects are enormous.
About Alexandria Real Estate Equities, Inc.
Alexandria
Real Estate Equities, Inc. (NYSE: ARE), an S&P 500®
company, is a best-in-class, mission-driven life science REIT
making a positive and lasting impact on the world. As the pioneer
of the life science real estate niche since its founding in 1994,
Alexandria is the preeminent and
longest-tenured owner, operator and developer of collaborative life
science, agtech and technology campuses in AAA innovation cluster
locations, including Greater
Boston, the San Francisco Bay
Area, New York City,
San Diego, Seattle, Maryland and Research Triangle. The trusted
partner to over 1,000 tenants, as of September 30, 2022, Alexandria has a total market capitalization
of $33.3 billion and an asset base in
North America of 74.5 million SF,
which includes 41.1 million RSF of operating properties and 5.6
million RSF of Class A properties undergoing construction, 9.9
million RSF of near-term and intermediate-term development and
redevelopment projects and 17.9 million SF of future development
projects. Alexandria has a
longstanding and proven track record of developing Class A
properties clustered in life science, agtech and technology
campuses that provide our innovative tenants with highly dynamic
and collaborative environments that enhance their ability to
successfully recruit and retain world-class talent and inspire
productivity, efficiency, creativity and success. Alexandria also provides strategic capital to
transformative life science, agrifoodtech, climate innovation and
technology companies through our venture capital platform. We
believe our unique business model and diligent underwriting ensure
a high-quality and diverse tenant base that results in higher
occupancy levels, longer lease terms, higher rental income, higher
returns and greater long-term asset value. For additional
information on Alexandria, please
visit www.are.com.
Forward-Looking Statements
This press release
includes "forward-looking statements" within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended. Such
forward-looking statements include, without limitation, statements
regarding the likelihood of continued investment activity by the
Alexandria Venture Investments platform and the potential impacts
of such investments on Alexandria's business, mission, relationships,
the companies in which it invests, current and future healthcare
challenges, healthcare costs and the broader life science,
agrifoodtech and climate innovation industries. These
forward-looking statements are based on the company's present
intent, beliefs or expectations, but forward-looking statements are
not guaranteed to occur and may not occur. Actual results may
differ materially from those contained in or implied by the
company's forward-looking statements as a result of a variety of
factors, including, without limitation, the risks and uncertainties
detailed in its filings with the Securities and Exchange
Commission. All forward-looking statements are made as of the date
of this press release, and the company assumes no obligation to
update this information. For more discussion relating to risks and
uncertainties that could cause actual results to differ materially
from those anticipated in the company's forward-looking statements,
and risks and uncertainties to the company's business in general,
please refer to the company's filings with the Securities and
Exchange Commission, including its most recent annual report on
Form 10-K and any subsequently filed quarterly reports on Form
10-Q.
CONTACT: Sara
Kabakoff, Vice President – Strategic Communications,
(626) 788–5578, skabakoff@are.com
View original
content:https://www.prnewswire.com/news-releases/alexandria-venture-investments-ranked-as-1-most-active-corporate-investor-in-biopharma-for-sixth-consecutive-year-301715732.html
SOURCE Alexandria Real Estate Equities, Inc.